Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway
Advances in Clinical and Experimental Medicine · 2023
DOI: 10.17219/acem/170184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Zhijin Lu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Trauma Surgery Emergency Center, Ganzhou People's Hospital, China. Hauptthemen laut MEDLINE: Glioblastoma, Apoptosis, Sesquiterpenes, Cell Proliferation. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
BACKGROUND: Glioblastoma multiforme (GBM) is a lethal brain tumor with high mortality and morbidity. Nerolidol (NRD) is a sesquiterpene alcohol sequestered from the essential oils of aromatic florae with potent antioxidant, antiviral, anticancer, cardioprotective, and neuroprotective activity. OBJECTIVES: The aim of the study was to investigate the underlying cell-cycle mechanisms of NRD-mediated antiproliferative and apoptosis activities in GBM using human U-251 cells. MATERIAL AND METHODS: The current research investigated the antiproliferative and apoptotic activities of NRD on U-251 cells. The effects of NRD were measured using a Cell Counting Kit-8 (CCK-8) assay, 4',6-diamidino-2-phenylindole (DAPI) staining, messenger ribonucleic acid (mRNA) level assessment, and western blot assay. RESULTS: Nerolidol decreased U-251 viability in a dose-dependent manner, as well as induced apoptotic activity, reduced B-cell lymphoma-2 (BCL-2) levels, and increased mRNA expression of BCL-2-associated X (Bax), caspase-3 and caspase-9. The attenuation of the cyclin-D1, cyclin-dependent kinase 4 (CDK4) and CDK6 mRNA expression confirmed cell cycle regulation. Western blot analysis of CDK1 indicated reductions in cyclin-B1 and p21. Furthermore, NRD prompted apoptosis through p38 amelioration and increased phosphorylated extracellular signal-related kinase 1 (p-ERK1) and phosphorylated c-Jun N-terminal protein kinase 1 (p-JNK1) levels. CONCLUSIONS: Nerolidol inhibited GBM cell viability and induced apoptosis through the regulation of cell-cycle proteins via p38 mitogen-activated protein kinase (MAPK) signaling pathways. Thus, NRD could be developed as a potential natural therapeutic agent for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Trauma Surgery Emergency Center, Ganzhou People's Hospital, China.
- Physical Examination Center, Ganzhou People's Hospital, China.
- Surgical Intensive Care Unit, Xi'an Children's Hospital, China.
- Department of Neurosurgery, Xi'an Children's Hospital, China.
Zitieren
APA
Lu, Z., Tang, T., Huang, J., & Shi, Y. (2023). Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/170184
Vancouver
Lu Z, Tang T, Huang J, Shi Y. Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/170184
BibTeX
@article{Lu2023,
author = {Lu, Zhijin and Tang, Tao and Huang, Juan and Shi, Yongqiang},
title = {Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway},
journal = {Advances in Clinical and Experimental Medicine},
year = {2023},
doi = {10.17219/acem/170184}
}
EUVIMED